These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 11193552)

  • 1. [Comparison of cost and benefits of each model for rubella immunization in Japan].
    Terada K; Niizuma T; Daimon Y; Kataoka N
    Kansenshogaku Zasshi; 2000 Dec; 74(12):1012-7. PubMed ID: 11193552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Economic evaluation on different two-dose-vaccination-strategies related to Measles, Mumps and Rubella Combined Attenuated Live Vaccine].
    He HQ; Zhang B; Yan R; Li Q; Fu J; Tang XW; Zhou Y; Deng X; Xie SY
    Zhonghua Liu Xing Bing Xue Za Zhi; 2016 Aug; 37(8):1121-6. PubMed ID: 27539345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States.
    Zhou F; Reef S; Massoudi M; Papania MJ; Yusuf HR; Bardenheier B; Zimmerman L; McCauley MM
    J Infect Dis; 2004 May; 189 Suppl 1():S131-45. PubMed ID: 15106102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Antibody persistence following on different vaccination strategies of domestic measles, mumps and rubella combined attenuated live vaccine: a 3-year follow-up study].
    He HQ; Li Q; Yan R; Zhou Y; Tang XW; Deng X; Xie SY; Chen ZP
    Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Apr; 51(4):336-340. PubMed ID: 28395468
    [No Abstract]   [Full Text] [Related]  

  • 5. Economic analysis of measles elimination program in the Republic of Korea, 2001: a cost benefit analysis study.
    Bae GR; Choe YJ; Go UY; Kim YI; Lee JK
    Vaccine; 2013 May; 31(24):2661-6. PubMed ID: 23602654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefits, risks and costs of immunization for measles, mumps and rubella.
    White CC; Koplan JP; Orenstein WA
    Am J Public Health; 1985 Jul; 75(7):739-44. PubMed ID: 3923849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
    Zäch K; Nicoara C; Germann D; Matter L
    Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Accumulative vaccination rate of rubella and positive antibody rate in an area of Japan--future problems with rubella].
    Terada K; Niizuma T; Daimon Y; Kataoka N
    Kansenshogaku Zasshi; 1999 Oct; 73(10):1038-41. PubMed ID: 10565119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling the Transmission of Measles and Rubella to Support Global Management Policy Analyses and Eradication Investment Cases.
    Thompson KM; Badizadegan ND
    Risk Anal; 2017 Jun; 37(6):1109-1131. PubMed ID: 28561947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rubella virus neutralizing antibody response after a third dose of measles-mumps-rubella vaccine in young adults.
    McLean HQ; Fiebelkorn AP; Ogee-Nwankwo A; Hao L; Coleman LA; Adebayo A; Icenogle JP
    Vaccine; 2018 Sep; 36(38):5732-5737. PubMed ID: 30107992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001.
    Zhou F; Santoli J; Messonnier ML; Yusuf HR; Shefer A; Chu SY; Rodewald L; Harpaz R
    Arch Pediatr Adolesc Med; 2005 Dec; 159(12):1136-44. PubMed ID: 16330737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody persistence in children aged 6-7years one year following booster immunization with two MMR vaccines applied by aerosol or by injection.
    Díaz Ortega JL; Castaneda D; Arellano Quintanilla DM; Martínez D; Trumbo SP; Fernández de Castro J
    Vaccine; 2017 May; 35(23):3116-3122. PubMed ID: 28457672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic analyses of rubella and rubella vaccines: a global review.
    Hinman AR; Irons B; Lewis M; Kandola K
    Bull World Health Organ; 2002; 80(4):264-70. PubMed ID: 12075361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccines.
    Schwarzer S; Reibel S; Lang AB; Struck MM; Finkel B; Gerike E; Tischer A; Gassner M; Glück R; Stück B; Cryz SJ
    Vaccine; 1998; 16(2-3):298-304. PubMed ID: 9607046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measles, mumps, and rubella antibody patterns of persistence and rate of decline following the second dose of the MMR vaccine.
    Seagle EE; Bednarczyk RA; Hill T; Fiebelkorn AP; Hickman CJ; Icenogle JP; Belongia EA; McLean HQ
    Vaccine; 2018 Feb; 36(6):818-826. PubMed ID: 29317117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Increasing the immunization rate against measles, mumps, and rubella in medical students at the University of Berne].
    Germann D; Matter L
    Schweiz Med Wochenschr; 1999 Apr; 129(13):499-507. PubMed ID: 10322563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevaccination antibody screening and immunization program for healthcare personnel against measles, mumps, rubella, and varicella in a Japanese tertiary care hospital.
    Kanamori H; Tokuda K; Ikeda S; Endo S; Ishizawa C; Hirai Y; Takahashi M; Aoyagi T; Hatta M; Gu Y; Yano H; Weber DJ; Kaku M
    Tohoku J Exp Med; 2014 Oct; 234(2):111-6. PubMed ID: 25224029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immunization Programme and Coverage against Measles and Rubella in Spain. Challenges for Achieving their Elimination].
    Limia Sánchez A; Molina Olivas M
    Rev Esp Salud Publica; 2015; 89(4):357-64. PubMed ID: 26580791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Measles, mumps and rubella: vaccination rate and seroprevalence in 8th grade students of 8 different sites in Switzerland 1995/96].
    Stohrer-Draxl P; Amstad H; Grize L; Gassner M; Takken-Sahli K; Bourquin C; Braun-Fahrländer C
    Praxis (Bern 1994); 1999 Jun; 88(24):1069-77. PubMed ID: 10420798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The virtual elimination of rubella and mumps from the United States and the use of combined measles, mumps and rubella vaccines (MMR) to eliminate measles.
    Bart KJ; Orenstein WA; Hinman AR
    Dev Biol Stand; 1986; 65():45-52. PubMed ID: 3104117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.